Shots: The EMA submission is based on P-III ‘1053’ study results assessing Lumoxiti monothx in patients with r/r HCL who have received at least two prior therapies, including one purine […]readmore
Tags : Hairy Cell Leukemia
Shots: The approval is based on P-III ‘1053’ trial conducted across 34 sites in 14 countries assessing Lumoxiti (moxetumomab pasudotox-tdfk) in patients with r/r HCL, testing its safety, efficacy, immunogenicity […]readmore